FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average	burden									
hours per response	: 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Ware Olivia C				- 3. E	Issuer Name and Ticker or Trading Symbol Contineum Therapeutics, Inc. [CTNM] Date of Earliest Transaction (Month/Day/Year) 05/24/2024							(Ch	5. Relationship of Reporting F Check all applicable) X Director Officer (give title below)			10% Ow Other (s	ner	
(Last) (First) (Middle) 10578 SCIENCE CENTER DRIVE, SUITE 200					4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SAN DII	EGO CA	A 9	92121											X Form f	iled by Mor		orting Person	
(City)	(St	ate) ((Zip)		Ru	Rule 10b5-1(c) Transaction Indication												
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											d to							
		Tab	le I - Nor	n-Deriv	ative	Sec	curitie	s Ac	quired, D)isp	osed o	of, or Be	neficial	ly Owned	i			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,		, Transaction Disposed Code (Instr. 5)		rities Acquired (A) or ed Of (D) (Instr. 3, 4 ar		Benefici	es ally Following	Form (D) or	orm: Direct D) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	/	Amount	t (A) or Pi		Transac	nsaction(s) tr. 3 and 4)			(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date Execution (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,		Transaction Code (Instr.		tive ties ed sed 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ownersh Form: Direct (D or Indirec (I) (Instr.	Ownership	Beneficial Ownership ct (Instr. 4)	
c					Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$15.76	05/24/2024			A		3,700		(1)	05	/23/2034	Class A Common Stock	3,700	\$0	3,700		D	

Explanation of Responses:

1. Options granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Program, as amended. One-third of the option shares vest on April 5, 2025, and the remainder vests in 24 equal monthly installments thereafter, subject to the Reporting Person's continuous service.

/s/ Peter Slover, Attorney-in-

Fact

** Signature of Reporting Person Date

05/29/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.